Analysis of Patients Treated with Cisplatin or Carboplatin-Based Doublet Chemotherapy in the European Frame Observational Study

Abstract

ABSTRACT Aim: FRAME was a prospective observational study of patients (pts) receiving platinum (plt)-based chemotherapy as first-line treatment (FLT) for advanced or metastatic non-small cell lung cancer (NSCLC) across Europe between 2009 and 2012. Methods: The study primary objective of overall survival was previously reported. Here, we describe the association between baseline characteristics and the physician's choice of a cisplatin (cis) or carboplatin (cb) backbone for FLT observed in FRAME. The distribution of baseline characteristics was compared by t-test or k2-test and summarized by propensity of receiving cb estimated by logistic regression. Cohorts were matched by propensity score; survival for matched pts was compared using Kaplan-Meier approach. Results: In total, 1520 pts received either cis (n = 825) or cb (n = 695) in combination with either: pemetrexed, gemcitabine, taxanes or vinorelbine, and were analyzed here. Pts prescribed cb were on average older, had worse ECOG PS and were more likely to have squamous histology than pts who received cis (Table 1); they also had more pre-existing conditions (cardiovascular p Cis (n = 825) Cb (n = 695) p-value ≥70 yrs (%) 15 47 ECOG PS (%) Gr 0-1 Gr 2-3 87 12 77 22 FLT (+plt) (%) pemetrexed (n = 567) gemcitabine (n = 360) taxanes (n = 293) vinorelbine (n = 300) 47 23 9 21 26 24 31 19 Histology (%) Squamous (sq) Non-sq 23 75 26 70 .031 Conclusions: FRAME observed that age, ECOG PS, pre-existing conditions and pathological diagnosis have strong associations with the choice of cis or cb in FLT for advanced or metastatic NSCLC across Europe. Disclosure: D. Moro-Sibilot: Consulting fees from Eli Lilly and Company, Roche, Astra Zeneca, Boehringer Ingelheim France, Amgen; J. De Castro Carpeno: Speakers Bureau for Roche; Advisory board for Eli Lilly and Company, Roche and Pfizer; K. Kmak-Lesniewski: Invited speaker for Eli Lilly, Roche, Astra Zeneca, GSK, Amgen; J.G. Aerts: Research grant from and Consultant for Eli Lilly and Company. Advisory board for Eli Lilly and Company, Roche Genentech and BMS; R. Villatoro: Speaker fee from Jansen, Pfizer; K. Kraaij: Employee and stockholder of Eli Lilly and Company; K. Nacerddine: Employee and stockholder of Eli Lilly and Company; Y. Dyachkova: Employee and stockholder of Eli Lilly and Company; K. Smith: Employee of Eli Lilly and Company; A. Girvan: Employee and stockholder of Eli Lilly and Company; C.M. Visseren-Grul: Employee and stockholder of Eli Lilly and Company; P.A. Schnabel: Speakers Bureau for AstraZeneca, InterMune, Eli Lilly and Company, Novartis, Pfizer, Roche. Advisory board for AstraZeneca, Eli Lilly and Company, Novartis, Roche. Prior research funding from Eli Lilly and Company. All other authors have declared no conflicts of interest.